Jiankui He: A Sorry Tale of High-Stakes Science
By Landon J. Getz, Graham Dellaire, Francoise Baylis,
Hastings Bioethics Forum
| 12. 10. 2018
In response to news of the world’s first babies born in China from gene-edited embryos, Sam Sternberg, a CRISPR/Cas9 researcher at Columbia University, spoke for many when he said“I’ve long suspected that scientists, somewhere, would rush to claim the ‘prize’ of being first to apply CRISPR clinically to edit the DNA of human embryos, and use those embryos to establish pregnancies, but still, I’m shocked to find out it’s allegedly happened this quickly.”
There is considerable irony in Sternberg’s “shock” at the birth announcement by Jiankui He of the Southern University of Science and Technology in China, insofar as modern science (and especially frontier science) encourages competition, rewards high-performance (typically measured in terms of publications in high-impact journals, research dollars from prestigious granting agencies, lucrative patents, and promising start-ups), and celebrates “firsts” often with considerable pomp and ceremony. For chemistry, physics and physiology the most prestigious of these accolades is the Nobel Prize. As Ben Hurlbut, of Arizona State University, has remarked, He was “acting in line with” a scientific culture “that puts a premium on provocative research, celebrity...
Related Articles
By Carl Zimmer, The New York Times | 10.20.2026
For the first time, scientists say they have used viruses designed by artificial intelligence to treat a human patient.
Researchers announced on Tuesday that they had administered the virus, known as a phage, to a patient suffering from a deadly...
By Noah Fromson, HealthLab | 10.19.2026
Gene therapy is no longer the future of medicine — it’s reality. Treatments that replace, silence or edit genes are already changing clinical care.
There are more than 6,000 rare genetic disorders but only a fraction currently have treatable targets...
By Roxanne Khamsi, The Atlantic | 10.16.2026
In recent months, news came out about several distressing cases that have underscored the risks of gene therapy, which delivers DNA to a patient’s cells to treat disease. All of these cases have one thing in common that’s not apparent...
By Rebecca Roberts, The Scientist | 10.11.2026
Heritable genome editing in human embryos is once again under intense scrutiny after the publication of an opinion piece in Trends in Genetics at the end of last month.1 In the paper, Cathy Tie, the founder and chief...